Overview

* PTC Therapeutics ( PTCT ) Q3 revenue rises to $211 mln, helped by Sephience launch

* PTC reports Q3 net income of $15.9 mln, reversing previous year's loss of $106.7 mln

Outlook

* PTC expects full-year 2025 revenue of $750 mln to $800 mln

* Company projects 2025 GAAP R&D and SG&A expenses of $805 mln to $835 mln

* PTC anticipates 2025 non-GAAP R&D and SG&A expenses of $730 mln to $760 mln

Result Drivers

* SEPHIENCE LAUNCH - Strong initial uptake of Sephience with $19.6 mln in Q3 revenue and 521 start forms in the US

* ROYALTY REVENUE - Increase in royalty revenue to $70.8 mln, driven by Evrysdi sales

* DMD FRANCHISE DECLINE - Revenue from DMD franchise decreased, with Translarna and Emflaza revenues lower than previous year

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $130.96

Product mln

Revenue

Q3 Net $15.89

Income mln

Q3 Basic $0.20

EPS

Q3 $207.99

Operatin mln

g

Expenses

Q3 $3.01

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 5 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for PTC Therapeutics Inc ( PTCT ) is $70.00, about 3% above its November 3 closing price of $67.93

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)